Related Experiment Video
Updated: Jul 10, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Third Division, Department of Internal Medicine, Kyoto University Hospital, Kyoto, Japan.
Insights
Vesnarinone improved survival and reduced heart damage in a murine heart failure model by inhibiting cytokine production, including tumor necrosis factor-alpha. This suggests reducing cytokine release may be key to vesnarinone
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Cytokines are increasingly recognized as key factors in heart failure pathogenesis and pathophysiology.
- Elevated circulating cytokine levels are observed in heart failure patients.
- Certain cytokines can negatively impact myocardial contractility both in vitro and in vivo.
Purpose of the Study:
- To investigate the effects of vesnarinone on cytokine production in a murine model of congestive heart failure.
- To determine if vesnarinone's beneficial effects on heart failure are related to its impact on cytokine regulation.
Main Methods:
- Utilized a murine model of congestive heart failure induced by encephalomyocarditis virus infection.
- Administered vesnarinone treatment to assess its impact on survival and myocardial damage.
- Measured natural killer cell activity and the production of tumor necrosis factor-alpha (TNFalpha).
- Assessed cytokine production by peripheral blood and endothelial cells following vesnarinone treatment.
Main Results:
- Vesnarinone treatment significantly improved survival and reduced myocardial damage in the heart failure model.
- Vesnarinone inhibited the increase in natural killer cell activity and TNFalpha production.
- The drug also suppressed the production of various cytokines by peripheral blood and endothelial cells.
Conclusions:
- Vesnarinone plays a significant role in regulating cytokine production.
- Reduction in cytokine release may contribute to the therapeutic benefits of vesnarinone in heart failure treatment.
- Further research into cytokine-modulating inotropic agents could lead to better heart failure therapies.
Abstract:
Cytokines are being increasingly recognised as important factors in the pathogenesis and pathophysiology of heart failure. Elevated levels of circulating cytokines have been reported in patients with heart failure, and various cytokines have been shown to depress myocardial contractility in vitro and in vivo. In our murine model of congestive heart failure resulting from encephalomyocarditis virus infection, survival and myocardial damage were markedly improved by treatment with vesnarinone. Vesnarinone inhibited the increase in natural killer cell activity and production of tumour necrosis factor-alpha (TNFalpha) in this animal model. Vesnarinone also inhibited the production of various cytokines by peripheral blood and by endothelial cells. These findings provide evidence that vesnarinone plays an important role in the regulation of cytokine production, and suggest that the reduction of cytokine release may contribute to the beneficial effects of the drug for the treatment of heart failure. As we learn more about the pathophysiological and pathogenetic role of cytokines in heart failure, it should be possible to design better and more targeted pharmacological agents. Furthermore, the investigation of inotropic agents that are effective against the production of cytokines may help in the classification of these agents.
